Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)

D. J. Inwards; P. A. Fishkin; B. R. Laplant; M. T. Drake; P. J. Kurtin; D. A. Nikcevich; D. B. Wender; B. S. Lair; T. E. Witzig

doi:10.1093/annonc/mdx814

Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)

D. J. Inwards, P. A. Fishkin, B. R. Laplant, M. T. Drake, P. J. Kurtin, D. A. Nikcevich, D. B. Wender, B. S. Lair, T. E. Witzig

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The following funding statement was missing from the original manuscript: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Also supported in part by funds from Wyeth Pharmaceuticals. Wyeth was subsequently purchased by Pfizer Pharmaceuticals. This has now been amended in the online version.

Original language	English (US)
Pages (from-to)	346
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdx814
State	Published - Feb 1 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdx814

Cite this

Inwards, D. J., Fishkin, P. A., Laplant, B. R., Drake, M. T., Kurtin, P. J., Nikcevich, D. A., Wender, D. B., Lair, B. S., & Witzig, T. E. (2019). Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273). Annals of Oncology, 30(2), 346. https://doi.org/10.1093/annonc/mdx814

Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273). / Inwards, D. J.; Fishkin, P. A.; Laplant, B. R. et al.
In: Annals of Oncology, Vol. 30, No. 2, 01.02.2019, p. 346.

Research output: Contribution to journal › Comment/debate › peer-review

Inwards, DJ, Fishkin, PA, Laplant, BR, Drake, MT, Kurtin, PJ, Nikcevich, DA, Wender, DB, Lair, BS & Witzig, TE 2019, 'Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)', Annals of Oncology, vol. 30, no. 2, pp. 346. https://doi.org/10.1093/annonc/mdx814

@article{6b573f15e72e4359a5f9ac81e6455493,

title = "Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)",

abstract = "The following funding statement was missing from the original manuscript: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Also supported in part by funds from Wyeth Pharmaceuticals. Wyeth was subsequently purchased by Pfizer Pharmaceuticals. This has now been amended in the online version.",

author = "Inwards, {D. J.} and Fishkin, {P. A.} and Laplant, {B. R.} and Drake, {M. T.} and Kurtin, {P. J.} and Nikcevich, {D. A.} and Wender, {D. B.} and Lair, {B. S.} and Witzig, {T. E.}",

note = "Publisher Copyright: {\textcopyright} VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.",

year = "2019",

month = feb,

day = "1",

doi = "10.1093/annonc/mdx814",

language = "English (US)",

volume = "30",

pages = "346",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Erratum

T2 - Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)

AU - Inwards, D. J.

AU - Fishkin, P. A.

AU - Laplant, B. R.

AU - Drake, M. T.

AU - Kurtin, P. J.

AU - Nikcevich, D. A.

AU - Wender, D. B.

AU - Lair, B. S.

AU - Witzig, T. E.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The following funding statement was missing from the original manuscript: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Also supported in part by funds from Wyeth Pharmaceuticals. Wyeth was subsequently purchased by Pfizer Pharmaceuticals. This has now been amended in the online version.

AB - The following funding statement was missing from the original manuscript: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Also supported in part by funds from Wyeth Pharmaceuticals. Wyeth was subsequently purchased by Pfizer Pharmaceuticals. This has now been amended in the online version.

UR - http://www.scopus.com/inward/record.url?scp=85061959266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061959266&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx814

DO - 10.1093/annonc/mdx814

M3 - Comment/debate

C2 - 29390098

AN - SCOPUS:85061959266

SN - 0923-7534

VL - 30

SP - 346

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -

Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this